[
  {
    "ts": null,
    "headline": "HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View",
    "summary": "HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.",
    "url": "https://finnhub.io/api/news?id=97299383d6e49aaff863cb8ef177a23cc6a298378fddbe4daca7b30367a5854e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753463460,
      "headline": "HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View",
      "id": 136090872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.",
      "url": "https://finnhub.io/api/news?id=97299383d6e49aaff863cb8ef177a23cc6a298378fddbe4daca7b30367a5854e"
    }
  },
  {
    "ts": null,
    "headline": "Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic",
    "summary": "The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable",
    "url": "https://finnhub.io/api/news?id=129609ac9ded3ebd6a9c645a90ed70bbf28b0f1a3158486a2cdbc8e7bad1ca16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753456380,
      "headline": "Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic",
      "id": 136088609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable",
      "url": "https://finnhub.io/api/news?id=129609ac9ded3ebd6a9c645a90ed70bbf28b0f1a3158486a2cdbc8e7bad1ca16"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott",
    "summary": "The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Acut",
    "url": "https://finnhub.io/api/news?id=7c4701b878990b06be67ef096b1ab67b505046912b391faa02130abaee324222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753435620,
      "headline": "U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott",
      "id": 136084939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Acut",
      "url": "https://finnhub.io/api/news?id=7c4701b878990b06be67ef096b1ab67b505046912b391faa02130abaee324222"
    }
  }
]